Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

APT for HER2 breast cancer patients with small tumours

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.01.19
Views: 409

Prof Nagi El Saghir - American University of Beirut, Beirut, Lebanon

Prof Nagi El Saghir speaks to ecancer at BGICC 2019 in Cairo about APT (adjuvant paclitaxel and trastuzumab) for HER2 small tumours.

He provides an overview of the current treatment options for varying tumour types, including support for the recent PERSEPHONE and APHINITY trials.

Prof El Saghir finishes by outlining the situation in Lebanon, and how hospitals here manage with certain limits on resources.

Related videos


no rating
Cancer care in Latin America

follow us

Breast Cancer CDK 4/6

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation